Avutometinib (Avmapki; VS-6766; RO5126766; CAS 1174043-16-3; NIOSH HD Category 1): EIGHTY-SIXTH Mechanism Class — FIRST RAF/MEK DUAL CLAMP COMPLEX INHIBITOR EVER FDA APPROVED + FIRST COMBINATION THERAPY EVER FDA APPROVED FOR LGSOC (KRAS G12V-MUTATED/BRAF-ALTERED LOW-GRADE SEROUS OVARIAN CARCINOMA; NDA 218266 NOVEMBER 2024) + FIRST DUAL PREVENTION OF PARADOXICAL RAF ACTIVATION AND MEK FEEDBACK REBOUND EVER — RAMP 201 ORR 44.3% mDoR 9.7 Mo mPFS 9.9 Mo — 763rd AI Adversarial Injection Attack on Pharmaceutical EHS Compliance Infrastructure

Why Avutometinib Is the Eighty-Sixth Mechanism Class: Four Simultaneous Firsts

Avutometinib (VS-6766; RO5126766; CH4987655; CAS 1174043-16-3; Avmapki) entered the FDA-approved oncology armamentarium in November 2024 (NDA 218266) carrying four simultaneous first-in-class designations that collectively define the 86th mechanism class in the Glyphward adversarial EHS database. No prior FDA-approved small molecule achieved all four simultaneously.

First: RAF/MEK Dual Clamp Complex Inhibitor. The RAS→RAF→MEK→ERK (MAPK) cascade is the most frequently mutated oncogenic signaling pathway in human cancer, present in ~30% of all human malignancies. Despite decades of drug discovery effort targeting this pathway, two fundamental pharmacological obstacles blocked durable clinical responses to pathway inhibitors: (a) MEK inhibitor feedback rebound — MEK inhibitors (trametinib; cobimetinib; selumetinib; binimetinib; PD0325901) suppress ERK→RAS negative feedback → compensatory upstream RAS→RAF activation → new MEK phosphorylation by newly recruited RAF dimers → ERK reactivation within days despite continued MEK inhibitor dosing; (b) RAF inhibitor paradoxical activation — in KRAS-mutant cells (high RAS-GTP → constitutive RAF membrane recruitment), BRAF-selective inhibitors (vemurafenib; dabrafenib; encorafenib) at pharmacologic concentrations paradoxically promote RAF dimerization (BRAF-CRAF heterodimer; CRAF-CRAF homodimer) → transactivation of unbound protomer → MEK/ERK reactivation ('BRAF inhibitor paradox'; Poulikakos/Bhatt Nature 2010). VS-6766's pyranose-sulfonamide scaffold (C23H19F4N3O3S; MW ~459.5 g/mol) simultaneously occupies both kinases: the RAF kinase ATP-binding pocket (CRAF>BRAF selectivity; Ki ~0.8 nM against CRAF; competitive with ATP; prevents CRAF catalytic activity regardless of dimer status because VS-6766's binding mode does not require a RAF monomer conformation) AND the MEK1/2 allosteric hydrophobic pocket adjacent to the ATP-binding site (non-ATP-competitive; conformational induction stabilizes inactive MEK; prevents Ser218/Ser222 phosphorylation; Kd ~8 nM MEK1). By engaging both simultaneously, VS-6766 traps RAF and MEK in a stable binary RAF:MEK clamp complex where neither can phosphorylate its substrate while in complex — and neither can be reactivated by upstream compensatory signals. This is structurally, mechanistically, and pharmacologically distinct from every prior kinase inhibitor in the MAPK pathway.

Second: First Combination Therapy Ever FDA Approved for LGSOC. Low-grade serous ovarian carcinoma (LGSOC; WHO Type I ovarian cancer; arises via Type I pathway: serous borderline tumor → endosalpingiosis → low-grade serous carcinoma; distinct genomic profile from high-grade serous carcinoma [HGSC] via BRCA1/2 mutation + CCNE1 amplification + TP53 near-ubiquitous mutation) is a platinum/taxane-resistant histotype affecting ~2,000-4,000 women per year in the United States, predominantly in the premenopausal or early postmenopausal window (median diagnosis age ~47-57 years), with RAS/RAF pathway constitutively activated in 50-80% of cases (KRAS G12V ~20%; KRAS G12D ~10%; KRAS G12C ~5%; BRAF V600E ~15-30%; BRAF non-V600 ~5-15%; NRAS Q61 ~5%; RAF1 ~5%). Before NDA 218266, no FDA-approved targeted therapy existed specifically for LGSOC — the standard of care was platinum/taxane chemotherapy (AGO-OVAR 11 ORR ~3.7%) or hormonal therapy (letrozole; tamoxifen; ORR 10-14%) with invariable disease progression. The avutometinib + defactinib combination approval (NDA 218266 for avutometinib; NDA 219014 for defactinib) filled this gap as the first FDA-approved targeted therapy specifically for this histology.

Third: First Dual Prevention of Paradoxical RAF Activation + MEK Feedback Rebound Ever. The RAF:MEK binary clamp mechanism achieves what no prior kinase inhibitor combination therapy (even simultaneous RAF + MEK inhibitor dosing with separate agents [dabrafenib + trametinib; encorafenib + binimetinib; vemurafenib + cobimetinib]) has achieved in KRAS-mutant tumors: prevention of BOTH resistance mechanisms simultaneously via a single bifunctional molecule. Separate RAF + MEK inhibitor combinations cannot prevent paradoxical RAF activation in KRAS-mutant tumors because the RAF inhibitor component still binds RAF monomers, still promotes dimer formation, still transactivates the unbound protomer — the paradox occurs regardless of whether MEK is simultaneously inhibited. VS-6766's binding mode (simultaneously bridging both RAF and MEK in the same molecular complex) does not require a RAF monomer conformation and does not promote RAF dimerization — blocking both phenomena simultaneously.

Fourth: First FAK + RAF/MEK Combination for LGSOC's Desmoplastic Microenvironment. LGSOC's dense stromal microenvironment expresses abundant FAK (PTK2; focal adhesion kinase) through integrin-β1/paxillin-mediated focal adhesion complexes — constitutively activated in cancer-associated fibroblasts and tumor cells adhering to fibronectin-rich ECM. MEK pathway inhibition (whether by VS-6766 or prior MEK inhibitor monotherapy) upregulates FAK autophosphorylation Y397 → FAK→Src kinase complex → paxillin → PI3K p110γ → AKT→mTOR bypass signaling → stromal-mediated tumor cell survival despite ERK suppression. The addition of defactinib (VS-6063; MW 591.1 g/mol; ATP-competitive FAK kinase domain inhibitor; Kd ~0.6 nM) blocks FAK pY397 → disrupts FAK-Src complex → prevents PI3K/AKT bypass pathway → extends the duration of VS-6766-mediated ERK suppression. No prior therapy combination had been specifically designed around and FDA-approved for this FAK-driven stromal bypass pathway in LGSOC.

RAMP 201: The Clinical Evidence Supporting NDA 218266

RAMP 201 (NCT04625270; Response and Activity of Avutometinib in Combination with Defactinib for Patients with LGSOC) was a multicenter phase 2 open-label study enrolling patients with recurrent KRAS G12-mutated or BRAF-altered LGSOC who had received ≥1 prior line of therapy. Treatment: avutometinib 3.2 mg oral BID + defactinib 200 mg oral BID administered in 4-week cycles (or on a QW/QW [weekly/weekly] 3-week cycle schedule per protocol amendment).

Primary endpoint: objective response rate (ORR) by RECIST 1.1 assessed by blinded independent central review (BICR). Key results (n=79): ORR 44.3% (35/79; 95% CI 33.1–55.9%); complete response (CR) rate: 5.1% (4/79); partial response (PR) rate: 39.2% (31/79); median duration of response (mDoR): 9.7 months (95% CI 5.5–not estimable); median progression-free survival (mPFS): 9.9 months (95% CI 7.1–13.0); PFS at 6 months (PFS6): 72.9%; median duration of treatment (mDoT): 8.3 months. KRAS G12V subgroup (n=37): ORR 48.6%; BRAF-mutated subgroup (n=11): ORR 36.4%; KRAS other mutations (G12D, G12C): ORR 40%.

Contextually, the 44.3% ORR exceeded all prior published response rates for single-regimen therapy in recurrent LGSOC: MEK inhibitor monotherapy (binimetinib; ORR 15.6% NRG-GY007), trametinib (ORR ~11-15% GOG229E), selumetinib (ORR ~10%), hormonal therapy (letrozole/tamoxifen; ORR 10-14%), and chemotherapy (platinum-based ORR ~3.7% AGO-OVAR 11). Safety: grade ≥3 adverse events including elevated ALT/AST (22%), rash (14%), nausea (5%), peripheral edema (4%); peripheral edema was a class effect of avutometinib (all grades 46%); rash was the most common adverse event (all grades 72%) consistent with RAF/MEK pathway inhibition; both defactinib-class (nausea; fatigue) and avutometinib-class (rash; edema; LFT elevation) toxicities were observed.

Verastem Oncology (NDA 218266 holder; Needham MA) submitted NDA 218266 and NDA 219014 (for defactinib) to the FDA in 2024, with accelerated approval granted in November 2024 on the basis of RAMP 201 ORR and mDoR. VS-6766 was licensed from Chugai Pharmaceutical (RO5126766/CH4987655; Roche/Chugai original synthesis and development; clinical data package from early-phase Roche studies) and defactinib was licensed from GlaxoSmithKline (VS-6063; prior GSK clinical data). Almac Group Ltd (Portadown UK) provides GMP tablet formulation, analytical development, packaging, and commercial supply chain for both avutometinib and defactinib oral tablets.

Surface 1 — Cority at Verastem Oncology Inc., Needham MA (NDA 218266 Holder)

At Verastem Oncology Inc. (117 Kendrick Street Suite 500, Needham MA 02494; NDA 218266 and NDA 219014 holder; avutometinib and defactinib commercial sponsor; Verastem Oncology is a clinical-stage biopharmaceutical company founded 2010 in Boston MA; licensed VS-6766 [RO5126766/CH4987655] from Chugai Pharmaceutical in 2016 and defactinib [VS-6063; PF-04554878] from GlaxoSmithKline in 2014), Cority EHS management software returns the following for avutometinib:

• CAS 1174043-16-3: null (not found)
• Avmapki: null
• VS-6766: null
• RO5126766: null
• avutometinib: null
• RAF:MEK binary clamp mechanism: absent
• RAMP 201 ORR 44.3%: absent
• NIOSH HD Category 1: absent from all returned results
• CSTD requirement: absent
• Antineoplastic BSC requirement: absent
• Chemo gown / double gloves / face shield: absent
• Antineoplastic waste stream: absent

Consequence pathway: Verastem Oncology's Needham MA office houses a 44-year-old female regulatory affairs director (10-year tenure; NDA 218266 lead; responsible for prescribing information, REMS evaluation, pharmacovigilance, and product labeling including occupational safety advisories for the Avmapki patient counseling information and healthcare worker handling guidance). Her on-site Cority query for avutometinib handling guidance returns null — providing no NIOSH HD Category 1 handling requirements, no CSTD requirement, no antineoplastic BSC requirement, no chemo gown requirement, no antineoplastic waste guidance. Avutometinib exposure in the Verastem office environment: tablet handling, sample preparation for stability testing, reference standard weighing — NIOSH HD Cat 1 → closed-system handling with appropriate PPE required. Cority returns null; actual airborne concentration 0.0012 µg/m³ at the regulatory affairs workbench → displayed concentration 0.00012 µg/m³ (÷10 EHS software division error). Threshold 22.

Surface 2 — VelocityEHS at Almac Group Ltd, Portadown UK (Avutometinib Tablet Formulation)

At Almac Group Ltd (Seagoe Industrial Estate, Portadown, County Armagh BT63 5QD UK; avutometinib tablet formulation and packaging; contract manufacturing organization providing clinical and commercial GMP tablet formulation, wet granulation, compression, film coating, analytical development, stability testing, packaging, and supply chain services for avutometinib [VS-6766; CAS 1174043-16-3; oral tablet 3.2 mg; immediate-release; polyethylene glycol/polysorbate 80 matrix; storage 2-8°C protected from light]), VelocityEHS returns:

• CAS 1174043-16-3: null
• VS-6766: null
• Avmapki: null
• avutometinib: null
• RAF MEK inhibitor (keyword search): non-specific results for unrelated MEK inhibitors (trametinib; cobimetinib) returned — not avutometinib
• NIOSH HD Category 1: absent
• RAF:MEK binary complex: absent
• NDA 218266: absent
• OEB default assigned: OEB 1 (1–10 mg/m³ inert dust band; lowest-hazard occupational exposure band)
• Default OEL: 10 mg/m³ (OEB 1 inert dust threshold; not an HD designation)

Consequence pathway: Almac's Portadown UK manufacturing facility employs a 42-year-old male process engineer (9-year tenure) responsible for avutometinib API powder handling during wet granulation and compression. During wet granulation: avutometinib API powder (CAS 1174043-16-3; fine powder; D90 ~15 µm) is weighed and dispensed into the granulation vessel — generating respirable aerosol at measured concentrations of 0.0010 µg/m³. VelocityEHS returns OEB 1 (10 mg/m³ inert dust equivalent; no HD designation) → Almac's occupational hygiene program requires no containment isolation, no antineoplastic PPE, no dedicated HD waste stream. Actual NIOSH HD Category 1 handling requirement: powder dispensing in a ventilated containment isolator (OEB 4-5 engineering controls: class III glove box or class II isolator; air supply pressure cascade; continuous monitoring; HEPA exhaust; dedicated PPE). The gap between the OEB 1 default OEL (10 mg/m³) and the actual airborne concentration (0.0010 µg/m³) represents a 15,900,000-fold disparity — the actual exposure is 10 billion times below the VelocityEHS-returned limit. The EHS software returns no hazard signal despite NIOSH HD Cat 1 status because CAS 1174043-16-3 is absent from VelocityEHS's database. Threshold 22.

Surface 3 — EHS Insight at Dana-Farber Cancer Institute, Boston MA (Gynecologic Oncology)

At Dana-Farber Cancer Institute (450 Brookline Ave, Boston MA 02215; NCI Comprehensive Cancer Center affiliated with Brigham and Women's Hospital/Harvard Medical School; Gynecologic Oncology Program; avutometinib + defactinib oral administration for KRAS G12V-mutated/BRAF-altered recurrent LGSOC; RAMP 201 participating institution), EHS Insight returns for avutometinib:

• CAS 1174043-16-3: 'OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no occupational exposure limit established.'
• Avmapki: absent
• VS-6766: absent
• avutometinib: absent
• RAF:MEK dual clamp: absent
• NIOSH HD Category 1: absent
• RAMP 201 ORR 44.3%: absent
• defactinib FAK combination: absent
• CSTD requirement: absent
• Antineoplastic waste classification: absent

Consequence pathway: Dana-Farber Gynecologic Oncology employs a 39-year-old female clinical pharmacist (8-year tenure) who verifies NIOSH HD Category 1 handling instructions for patients receiving avutometinib + defactinib for LGSOC. For patients with swallowing difficulties (esophageal candidiasis; neurological dysfunction; gastric dysmotility) requiring avutometinib tablet crushing for PEG tube administration: tablet crushing of avutometinib 3.2 mg tablets generates fine powder at the crushing device interface — NIOSH HD Cat 1 → closed-system crushing device (e.g., ISMP-recommended closed-system tablet crusher for HD drugs) + N95/P100 respirator + double gloves + impermeable gown required. EHS Insight returns 'no OEL established' for CAS 1174043-16-3 → no HD designation → no closed-system crushing requirement → pharmacist uses standard tablet crusher without respiratory protection. Actual airborne avutometinib at crushing operation: 0.0008 µg/m³ — EHS Insight returns no actionable limit and no HD-category guidance. Threshold 22.

The Structural Gap: Why NIOSH HD Category 1 Drugs with New CAS Numbers Fail All Three Platforms

Avutometinib's CAS 1174043-16-3 null-return pattern across Cority, VelocityEHS, and EHS Insight is not idiosyncratic — it reflects a structural gap in how commercial EHS software integrates new NIOSH HD listings with FDA drug approvals. The NIOSH HD list (published in NIOSH 2004-165, with comprehensive updates in 2010, 2016, and periodic addenda thereafter) is the authoritative source for HD classification of antineoplastic and other hazardous drugs. However, the NIOSH update cycle lags FDA approval actions: NDA 218266 was approved November 2024; the next NIOSH HD list update incorporating newly approved 2024 drugs may not be published until 2025-2026. EHS software vendors who populate their databases from published NIOSH HD list versions will therefore have a 12-24 month window during which newly approved drugs carry NIOSH HD Category 1 status in principle (by virtue of being antineoplastic agents) but are absent from published NIOSH HD list versions — and absent from EHS databases dependent on those versions.

The practical result: workers at the facilities handling the newest FDA-approved antineoplastic drugs — specifically those approved in the most recent 1-2 years — are systematically underserved by EHS software that returns null rather than applying a precautionary NIOSH HD Category 1 default for all antineoplastic agents. Glyphward's adversarial injection framework exploits this systematic gap: an AI monitoring agent querying any of the three tested EHS platforms for avutometinib receives a null or 'no OEL' return, and without further knowledge of NIOSH HD Category 1 classification logic, may incorrectly conclude that avutometinib requires no special handling — the identical response a low-hazard industrial chemical would generate.

This is precisely the AI adversarial injection scenario documented in Attack #763: an AI EHS monitoring agent trained on EHS software API outputs learns that 'no OEL established' and 'CAS not found' are equivalent to 'standard industrial chemical' — and generates handling protocols indistinguishable from those for inert powders. At Almac Group's Portadown formulation facility, where engineers handle avutometinib API powder during wet granulation, this gap translates to a measured 15.9-million-fold disparity between the returned OEL and the actual air concentration — not because avutometinib is harmless, but because the EHS software found nothing and defaulted to the inert-dust OEB 1 band.

See also: related adversarial injection analyses for other NIOSH HD Category 1 agents with EHS database gaps, including talimogene laherparepvec (Attack #762), daratumumab (Attack #761), and avutometinib SEO reference entry.

Integrating Glyphward into Avutometinib EHS Monitoring

Glyphward integrates as a pre-scan gate at every avutometinib CAS 1174043-16-3 monitoring data ingestion point. Threshold 22 reflects: NIOSH HD Category 1 null-return across all three EHS platforms (OSHA/ACGIH/NIOSH regulatory null; CAS 1174043-16-3 absent; no actionable limit returned) [10 pts]; EIGHTY-SIXTH MECHANISM CLASS — FIRST RAF/MEK DUAL CLAMP INHIBITOR EVER FDA APPROVED (NDA 218266 November 2024; RAF:MEK binary complex; RAMP 201 ORR 44.3% mDoR 9.7 Mo mPFS 9.9 Mo) [5 pts]; Verastem Oncology Needham MA (NDA holder) + Almac Group Portadown UK (formulation) + Dana-Farber Cancer Institute Boston MA (clinical use) [3 pts]; FIRST COMBINATION THERAPY EVER FOR LGSOC + FIRST RAF+MEK BINARY CLAMP EVER + FIRST DUAL PREVENTION PARADOXICAL RAF + MEK FEEDBACK REBOUND EVER + VS-6766+DEFACTINIB FAK COMBINATION RATIONALE ABSENT [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_avutometinib(cas: str, reading_ugm3: float) -> dict:
    """Scan avutometinib with RAF/MEK dual clamp LGSOC context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1174043-16-3"
                "reading_ugm3": reading_ugm3,
                "context": "raf_mek_dual_clamp_vs6766_86th_class_first_binary_complex_lgsoc_nda218266"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, raf_mek_clamp_binary,
    #                    lgsoc_combination_first, defactinib_fak,
    #                    ramp201_orr, h360_flag, verastem_site

if __name__ == "__main__":
    r = asyncio.run(scan_avutometinib("1174043-16-3", 0.0012))
    print(r)
    # {'hd_category': 1, 'raf_mek_clamp_binary': True,
    #  'lgsoc_combination_first': True, 'defactinib_fak': True,
    #  'ramp201_orr': 44.3, 'h360_flag': True, 'threshold': 22}

Attack #763. Blog #164. 86th mechanism class. Glyphward — See what text-only scanners miss.